Indication
Nixura® (Febuxostat) is indicated for the chronic management of hyperuricemia in adult patients with gout, per the approved label.
Mechanism of action
Febuxostat is a selective non-purine inhibitor of xanthine oxidase. By blocking the conversion of hypoxanthine → xanthine → uric acid, it lowers serum urate and, with continued therapy, reduces gouty flares.
Strengths
- •40 mg tablet
- •80 mg tablet
Composition
Per approved Indian product label - 40 mg and 80 mg Febuxostat tablet strengths.
Presentation
Refer to approved product label / pack insert.
For Healthcare Professionals
Initiate flare prophylaxis (colchicine or low-dose NSAID) for 3–6 months on starting urate-lowering therapy. No dose adjustment for mild-to-moderate renal impairment; reduce to 40 mg in severe (CrCl < 30 mL/min). Monitor LFTs.
This section is intended for use by registered medical practitioners only. All clinical decisions remain the prescriber's responsibility and should be informed by the current approved product label.
Notes for patients & caregivers
Acute flares may briefly worsen when you start treatment - this is expected; do not stop the medicine. Take exactly as prescribed.
These notes are for general awareness only and are not a substitute for medical advice. Please follow your treating physician's instructions and the directions on the dispensed product.
Storage
Store below 25°C.
Important
- • Nixura® is a prescription medicine. It must only be used on the advice of a registered medical practitioner.
- • Always refer to the current approved Indian product label / package insert for definitive prescribing information.
- • If you experience any quality or safety concern, please contact us or write to info@vyapitus.com.